Rein Therapeutics Inc. (RNTX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Rein Therapeutics Inc. (RNTX) closed at USD 0.59 on 2026-10-14, a change of -55.6 % over the past year, with a market capitalization of USD 54.18M.
Rein Therapeutics Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.59 |
| 2026-10-13 | 0.75 |
| 2026-10-12 | 0.79 |
| 2026-10-09 | 0.79 |
| 2026-10-08 | 0.77 |
| 2026-10-07 | 0.79 |
| 2026-10-06 | 0.82 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Rein Therapeutics Inc. key figures
- Previous close
- USD 0.59 (2026-10-14)
- 1-year change
- -55.6 %
- Market cap
- USD 54.18M
- Enterprise value
- USD 58.53M
- P/E ratio (trailing)
- -0.45
- P/E ratio (forward)
- n/a
- EPS (trailing)
- -1.39
- EPS (forward)
- n/a
- PEG ratio
- n/a
- Price to book
- 5.28
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 1.68
- Employees
- 10
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Rein Therapeutics Inc.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Rein Therapeutics Inc. and compare it with other stocks.
Analyze RNTXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Rein Therapeutics Inc. shares.